NEW YORK (GenomeWeb News) – PrognosDx Health and the Molecular Medicine Research Institute announced recently a broad collaborative R&D agreement aimed at using PrognosDx's technology for the development of a new class of epigenetic therapeutics.

The deal provides Palo Alto, Calif.-based PrognosDx with resources to launch CLIA lab services, including a prostate cancer prognosis test and predictive tests for other cancers, the partners said.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The president of France's National Research Agency has resigned, according to Nature News.

A senator wants a "right-to-try" provision in the US Food and Drug Administration funding bill, but an ethicist says at Stat News that it would undermine the role of clinical trials.

In PNAS this week: red algae Porphyra umbicalis genome, deep neural network model for sequencing peptides, and more.

The Guardian's Barbara Ellen has tried out some DNA testing services to see whether they provide valuable information.